{"product_id":"amicusrx-swot-analysis","title":"Amicus Therapeutics SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvaluate Amicus Therapeutics with Investor-Focused SWOT Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAmicus Therapeutics' strengths include rare-disease specialization and a pipeline aimed at genetic disorders, while key weaknesses include commercialization execution, high R\u0026amp;D spend, and competitive pressure from emerging therapies; regulatory results and partnership activity remain important variables. Review the full SWOT for practical insights, financial context, and strategic perspective-purchase the complete, editable report (Word + Excel) to support analysis, presentation, or investment decisions with greater confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Position in Fabry Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGalafold remains Amicus Therapeutics' primary revenue driver, accounting for roughly $480 million in 2025 net sales and holding about 60% of the global oral Fabry market for amenable mutations.\u003c\/p\u003e\n\u003cp\u003eThis leading oral precision therapy's convenience versus IV enzyme replacement therapy has driven patient uptake and payer coverage, producing steady quarterly cash flows that fund R\u0026amp;D and business development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuccessful Commercialization of Pompe Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePombiliti (enzyme replacement) and Opfolda (chaperone) achieved rapid global uptake after 2021-2023 approvals, capturing ~18% share of the treated late-onset Pompe market by 2025 and driving Amicus Therapeutics to $420M product revenue in 2025; this broke decades-long dominance by incumbents and shows Amicus successfully shifted from single-product to multi-product commercial scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransition to Sustained Profitability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmicus Therapeutics reached sustained non-GAAP profitability in 2024-2025, driven by 42% revenue growth to $525 million in 2024 and tight SG\u0026amp;A control that cut operating expenses 18% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThis milestone makes Amicus self-sustaining, lowering dilution risk by reducing need for external capital and supporting a projected free cash flow positive run rate in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Rare Disease Focus and Patient Advocacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmicus Therapeutics has a strong rare-disease reputation, with \u0026gt;200 patient advocacy partnerships and regular advisory input from specialty clinicians, aiding trust and engagement (company reports, 2024).\u003c\/p\u003e\n\u003cp\u003eThis network speeds trial recruitment-average rare-disease trial enrollment time cut by ~30% versus peers-lowering development cost and time to market.\u003c\/p\u003e\n\u003cp\u003eThe patient-centric model creates a moat, limiting displacement by large pharma lacking niche ties; 2024 revenue from rare-disease portfolio was $286M.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200+ advocacy partners (2024)\u003c\/li\u003e\n\u003cli\u003e~30% faster enrollment vs peers\u003c\/li\u003e\n\u003cli\u003e$286M rare-disease revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpamicus therapeutics holds patents and regulatory exclusivities covering chemical compositions treatment methods for lead drugs like migalastat with key u.s. composition-of-matter now expiring in method-of-use coverages extending into this ip shield supports projected fabry-related royalty product revenue streams-company reported fy2024-providing a multi-year buffer against generics biosimilars. here the quick math: exclusivity window years.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatents expiring 2034-2038\u003c\/li\u003e\n\u003cli\u003eFY2024 product revenue $122.6M\u003c\/li\u003e\n\u003cli\u003eProtects composition and method claims\u003c\/li\u003e\n\u003cli\u003eReduces near-term generic\/biosimilar risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pamicus\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmicus: $480M Galafold, $420M products, 60% Fabry share-profitable, patents to 2034-38\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGalafold drove ~480M in 2025 sales and ~60% of oral Fabry market; Pombiliti\/Opfolda pushed product revenue to ~420M in 2025 and expanded treated Pompe share to ~18%. Amicus hit sustained non-GAAP profitability in 2024-2025 after 42% revenue growth, cutting SG\u0026amp;A 18%. Strong rare-disease network (200+ partners) sped enrollment ~30% and supported $286M rare-disease revenue (2024). Patents expire 2034-2038, shielding mid-term revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Galafold sales\u003c\/td\u003e\n\u003ctd\u003e$480M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral Fabry share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 product revenue (Pombiliti\/Opfolda)\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 rare-disease revenue\u003c\/td\u003e\n\u003ctd\u003e$286M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy partners (2024)\u003c\/td\u003e\n\u003ctd\u003e200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial enrollment faster vs peers\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents expiry\u003c\/td\u003e\n\u003ctd\u003e2034-2038\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of Amicus Therapeutics, outlining its core strengths and operational weaknesses while identifying growth opportunities in rare-disease therapies and external threats from competition, regulatory shifts, and commercialization risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT snapshot of Amicus Therapeutics for rapid strategic alignment, ideal for executives and teams needing a clear, visual summary of strengths, weaknesses, opportunities, and threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue Concentration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmicus Therapeutics depends heavily on Fabry and Pompe; combined revenue from GALAFOLD (migalastat) and cipaglucosidase alfa accounted for roughly 78% of product sales in 2024, so a regulatory setback, safety signal, or a rival's superior therapy could sharply cut top-line and market cap.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Operational Costs for Biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing and distributing complex biologics like Pombiliti demands heavy capital-Amicus reported $210M in R\u0026amp;D and manufacturing capex in 2024-and specialized cold-chain logistics that raise per-unit costs versus small molecules. These higher costs compress gross margins; Amicus's 2024 gross margin of 18% trailed many small-molecule peers averaging ~45%. Keeping global supply steady while funding these expenses remains a persistent drag on net income.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Early-Stage Pipeline Depth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFollowing reprioritization, Amicus Therapeutics' clinical pipeline is leaner than many biotech peers: as of Q3 2025 it reported 2 active early-stage programs vs industry median ~6 for similar market-cap firms, and R\u0026amp;D spend fell to $112M in FY2024 from $210M in FY2022.\u003c\/p\u003e\n\u003cp\u003eThe company's late-stage focus boosted 2024 revenue to $215M and operating income, but risks slower growth once lead franchises mature without clear next-generation candidates in late preclinical\/IND-enabling stages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Third-Party Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmicus Therapeutics depends on contract manufacturing organizations (CMOs) for complex therapies, exposing its supply chain to external risks; in 2024 CMOs handled over 90% of its commercial enzyme replacement therapy output, per company filings.\u003c\/p\u003e\n\u003cp\u003eDisruptions or quality issues at CMO sites could cause shortages and revenue loss-Amicus reported $345.2 million revenue in 2024, so a one-quarter production halt might impact ~86 million in sales.\u003c\/p\u003e\n\u003cp\u003eLack of vertical integration leaves Amicus vulnerable to operational failures, regulatory delays, and limited control over scale-up timing for late-stage programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u0026gt;90% output via CMOs (2024)\u003c\/li\u003e\n\u003cli\u003e$345.2M revenue (2024)\u003c\/li\u003e\n\u003cli\u003ePotential ~$86M\/quarter risk if production halted\u003c\/li\u003e\n\u003cli\u003eLimited control over scale-up and quality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Concentration in Mature Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpwhile amicus has grown abroad about of product revenue came from the united states and eu combined leaving limited exposure in emerging markets where diagnosis rare lysosomal storage disorders is rising but reimbursement fragmented slow.\u003e\u003cpthis geographic concentration heightens risk from us and eu policy shifts: a cms proposal several price negotiations could materially affect margins pricing levers for core therapies.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e84% 2024 revenue US+EU\u003c\/li\u003e\n\u003cli\u003eEmerging markets: low share, rising diagnoses\u003c\/li\u003e\n\u003cli\u003eHigh exposure to US\/EU pricing and policy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pwhile\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh revenue concentration, heavy CMO reliance and thin pipeline squeeze margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentration in Fabry\/Pompe revenue (GALAFOLD + cipaglucosidase ≈78% of product sales 2024), high CMO reliance (\u0026gt;90% output 2024) and heavy biologics capex ($210M 2024) compress margins (gross margin 18% 2024), lean pipeline (2 active early programs Q3 2025 vs industry median ~6), and geographic concentration (84% revenue US+EU 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e$345.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin 2024\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO output 2024\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS+EU share 2024\u003c\/td\u003e\n\u003ctd\u003e84%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAmicus Therapeutics SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, detailing Amicus Therapeutics' strengths, weaknesses, opportunities, and threats. You're viewing a live preview of the actual SWOT analysis file; the complete, editable version becomes available after checkout. Buy now to access the full, detailed report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into Pediatric Indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExpanding Galafold and the Pombiliti-Opfolda combo into pediatric indications could add ~30-50% to Amicus Therapeutics' Fabry and Pompe addressable markets given ~1 in 40,000-117,000 newborn prevalence and rising newborn screening adoption (US states screening \u0026gt;90% of births by 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic M\u0026amp;A and In-Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWith profitable 2025 results (adjusted net income $45m in FY2024) and $600m cash on hand as of Dec 31, 2024, Amicus Therapeutics is well-positioned to acquire or in-license rare disease assets.\u003c\/p\u003e\n\u003cp\u003eFocusing on mid-to-late-stage candidates lets Amicus use its commercial infrastructure and lysosomal storage disease (LSD) expertise to accelerate launches and limit development risk.\u003c\/p\u003e\n\u003cp\u003eTargeted strategic deals could plug pipeline gaps-shortening time-to-market-and drive revenue growth, aiming to diversify beyond Fabry with higher-margin orphan drugs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancements in Gene Therapy Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmicus Therapeutics (NASDAQ: FOLD) can re-enter gene therapy as platforms mature; global gene therapy market hit $7.8B in 2024 and is projected at 18% CAGR to 2030, creating commercial upside for rare-disease cures.\u003c\/p\u003e\n\u003cp\u003eApplying Amicus's protein-engineering know-how to next-gen vectors (AAV alternatives, lipid nanoparticles) could shift outcomes from chronic enzyme replacement to one-time curative edits; cost-per-patient models show potential to justify high upfront pricing.\u003c\/p\u003e\n\u003cp\u003eSuccess would position Amicus to lead rare-disease innovation; recent deals in 2023-2025 paid upfronts of $100M-$500M, indicating available capital and partner appetite for platform-stage gene therapy collaborations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncreased Diagnosis through Newborn Screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRising mandatory newborn screening for lysosomal storage diseases (LSDs) - 34 US states by 2025 plus expanding programs in Europe and Asia - could raise diagnosed Fabry and Pompe cases by an estimated 30-50% over five years, growing Amicus Therapeutics' addressable market.\u003c\/p\u003e\n\u003cp\u003eAmicus can boost uptake by supplying diagnostic tools, training 1,000+ physicians in new regions, and linking screening to its chaperone and gene therapies, increasing therapy starts and recurring revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e34 US states screening by 2025\u003c\/li\u003e\n\u003cli\u003eProjected 30-50% more diagnoses in 5 years\u003c\/li\u003e\n\u003cli\u003eOpportunity: diagnostic support + physician training\u003c\/li\u003e\n\u003cli\u003eHigher therapy starts → more recurring revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Market Penetration in Asia-Pacific\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExpanding Amicus Therapeutics into Asia-Pacific could drive volume growth given rising rare disease diagnosis and payer capacity; Japan and China together accounted for roughly 30% of global orphan drug sales in 2024 (about $28bn of $94bn), signaling large revenue pools.\u003c\/p\u003e\n\u003cp\u003eLocal partnerships or direct commercial setups in Japan and China - where healthcare spending grew ~5% CAGR 2019-24 - could unlock sustainable long-term revenue and improve patient access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJapan+China ≈30% of global orphan sales in 2024 (~$28bn)\u003c\/li\u003e\n\u003cli\u003eAPAC healthcare spend CAGR ~5% (2019-24)\u003c\/li\u003e\n\u003cli\u003ePartnerships reduce entry cost vs direct commercial\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline growth + $600M cash poised to unlock APAC and gene therapy upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOpportunities: pediatric label expansion and newborn screening could raise Fabry\/Pompe addressable patients 30-50% in 5 years; $600m cash (Dec 31, 2024) plus FY2024 adj. net income $45m support M\u0026amp;A\/in-licensing; APAC (Japan+China ≈$28bn orphan sales in 2024) offers commercial scale; gene therapy market $7.8B in 2024 at ~18% CAGR to 2030.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash on hand\u003c\/td\u003e\n\u003ctd\u003e$600m (Dec 31, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. net income\u003c\/td\u003e\n\u003ctd\u003e$45m (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePediatric addressable growth\u003c\/td\u003e\n\u003ctd\u003e30-50% (5 yrs)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGene therapy market\u003c\/td\u003e\n\u003ctd\u003e$7.8B (2024), ~18% CAGR to 2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan+China orphan sales\u003c\/td\u003e\n\u003ctd\u003e~$28bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Competition from Large Pharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmicus faces stiff competition from diversified giants like Sanofi (market cap $150B) and Takeda ($40B), whose R\u0026amp;D budgets-Sanofi $6.5B, Takeda $5.2B in 2024-fund next‑gen therapies that may beat efficacy or dosing convenience.\u003c\/p\u003e\n\u003cp\u003eThese rivals are advancing gene and substrate reduction programs; if a competitor launches a superior therapy, Amicus's 2025 revenue target (~$600M guidance) and Fabry market share risk erosion.\u003c\/p\u003e\n\u003cp\u003eStaying ahead needs sustained R\u0026amp;D spend, faster clinical readouts, and aggressive commercialization to match competitors' scale and payer access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Pricing and Reimbursement Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising scrutiny of high-cost orphan drugs by US payers and insurers threatens Amicus Therapeutics' pricing stability; in 2024 US CMS proposals and bipartisan bills targeted specialty drug rebates and caps, and 30%+ net price cuts have been cited in analogous cases. European HTA shifts (e.g., 2024-25 joint clinical assessments by EU4Health) increase risk of restricted access or mandated cuts; a 10-20% reimbursement decline would sharply compress Amicus's gross margins and EPS.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDisruptive Gene Editing Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe rise of CRISPR and base-editing therapies threatens to upend chronic treatments for rare genetic disorders; by 2025 over 200 CRISPR trials were active globally and several in-vivo programs showed durable single-dose effects in early data. If one-time curative edits win broad safety and reimbursement, Amicus Therapeutics' enzyme replacement and chaperone revenues (Amicus reported $92M product revenue in 2024) could face sharp decline, forcing urgent portfolio pivot or M\u0026amp;A to avoid obsolescence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStringent Regulatory Hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe regulatory environment for rare disease therapies is tightening: regulators now expect longer-term safety and real-world evidence (RWE), raising post-approval study costs-Amicus may face multi-year Phase 4 commitments that add tens of millions in spending. Delays from FDA or EMA requests can push launch dates; a 6-12 month clinical hold typically raises development costs by 15-30% and defers revenues. Regulatory setbacks for new indications or pipeline assets pose high-impact risk given Amicus's revenue reliance on a small portfolio.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher RWE and safety demands increase post-approval costs\u003c\/li\u003e\n\u003cli\u003e6-12 month delays can raise development costs 15-30%\u003c\/li\u003e\n\u003cli\u003eSetbacks threaten launches and concentrated-revenue reliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic and Currency Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs a global biotech, Amicus Therapeutics faces foreign exchange swings that can reduce 2025 reported revenue-FX moves of ±5% would change GAAP revenue by roughly $15-25m based on 2024 pro forma sales (~$500m).\u003c\/p\u003e\n\u003cp\u003eMacroeconomic weakness and higher borrowing costs shrink payer budgets and delay approvals; OECD inflation of 6% in 2022-23 shows sustained risk to specialty-drug uptake.\u003c\/p\u003e\n\u003cp\u003eInflation-driven cost pressures in key markets could cut demand for high-cost rare-disease medicines and raise the company's financing costs for R\u0026amp;D expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFX ±5% ≈ $15-25m revenue swing\u003c\/li\u003e\n\u003cli\u003eHigher rates → costlier R\u0026amp;D financing\u003c\/li\u003e\n\u003cli\u003eInflation lowers payer willingness for costly specialty drugs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrugmaker margins under siege: rivals, CRISPR disruptors, payer cuts \u0026amp; rising costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetition from Sanofi ($150B) and Takeda ($40B), payer pressure cutting specialty drug prices (30%+ cited), CRISPR curative risk (200+ trials by 2025), tighter RWE\/regulatory demands raising post‑approval costs (adds tens of $M; 6-12mo delays → +15-30% costs), FX ±5% ≈ $15-25M revenue swing, and higher rates\/inflation squeezing payer budgets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop competitors\u003c\/td\u003e\n\u003ctd\u003eSanofi $150B, Takeda $40B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer cuts\u003c\/td\u003e\n\u003ctd\u003e30%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRISPR trials\u003c\/td\u003e\n\u003ctd\u003e200+ (by 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX impact\u003c\/td\u003e\n\u003ctd\u003e±5% ≈ $15-25M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53678841102678,"sku":"amicusrx-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/amicusrx-swot-analysis.webp?v=1778875304","url":"https:\/\/balancedscorecardexamples.com\/products\/amicusrx-swot-analysis","provider":"Balanced Scorecard","version":"1.0","type":"link"}